Moving from an ophthalmic company with lackluster earnings selling both devices and drugs for the eye, four years ago, Allergan brought in a new CEO to turn around the company. To profit from higher margin businesses, he has refocused Allergan as a specialty pharmaceutical company. Allergan hopes to profit from advantages that its peers in specialty pharmaceuticals don't possess; a great deal of cash generated by Botox, (already a $400 million product), a top-rated sales force, and an internal R&D capability that has a history of bringing to market products in-licensed at early stages. Allergan isn't nearly big enough to compare the breadth of its discovery operations or development pipeline to Big Pharma. Management must provide strategic focus to a mid-sized pharmaceutical company working in multiple non-overlapping markets.
by Mary Stuart
After humble beginnings in 1989 as an orphan drug for a rare facial twitching disorder known as blepharospasm, Botox has...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
